Persistent Salmonella enterica serovar Typhimurium infection increases the susceptibility of mice to develop intestinal inflammation by Schultz, B.M. et al.
Persistent Salmonella enterica 
serovar Typhimurium infection 
increases the susceptibility of Mice 
to Develop intestinal inflammation
May 2018 | Volume 9 | Article 11661
Original research
published: 29 May 2018
doi: 10.3389/fimmu.2018.01166
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Mats Bemark, 
University of Gothenburg, 
Sweden
Reviewed by: 
Emma Slack, 
ETH Zürich, Switzerland  
Paul King, 
Monash University, Australia
*Correspondence:
Susan M. Bueno  
sbueno@bio.puc.cl
Specialty section: 
This article was submitted 
to Mucosal Immunity, 
a section of the journal 
Frontiers in Immunology
Received: 01 November 2017
Accepted: 09 May 2018
Published: 29 May 2018
Citation: 
Schultz BM, Salazar GA, Paduro CA, 
Pardo-Roa C, Pizarro DP, Salazar-
Echegarai FJ, Torres J, Riedel CA, 
Kalergis AM, Álvarez-Lobos MM and 
Bueno SM (2018) Persistent 
Salmonella enterica serovar 
Typhimurium Infection Increases the 
Susceptibility of Mice to Develop 
Intestinal Inflammation. 
Front. Immunol. 9:1166. 
doi: 10.3389/fimmu.2018.01166
Bárbara M. Schultz1, Geraldyne A. Salazar1, Carolina A. Paduro1, Catalina Pardo-Roa1, 
Daniela P. Pizarro1, Francisco J. Salazar-Echegarai1, Javiera Torres2, Claudia A. Riedel3, 
Alexis M. Kalergis1,4, Manuel M. Álvarez-Lobos5 and Susan M. Bueno1*
1 Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de 
Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile, 2 Departamento de Anatomía Patológica, 
Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 3 Millennium Institute on Immunology and 
Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, 
Chile, 4 Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 
5 Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
Chronic intestinal inflammations are triggered by genetic and environmental components. 
However, it remains unclear how specific changes in the microbiota, host immunity, or 
pathogen exposure could promote the onset and exacerbation of these diseases. Here, 
we evaluated whether Salmonella enterica serovar Typhimurium (S. Typhimurium) infection 
increases the susceptibility to develop intestinal inflammation in mice. Two mouse models 
were used to evaluate the impact of S. Typhimurium infection: the chemical induction of 
colitis by dextran sulfate sodium (DSS) and interleukin (IL)-10−/− mice, which develop spon-
taneous intestinal inflammation. We observed that S. Typhimurium infection makes DSS-
treated and IL-10−/− mice more susceptible to develop intestinal inflammation. Importantly, 
this increased susceptibility is associated to the ability of S. Typhimurium to persist in liver and 
spleen of infected mice, which depends on the virulence proteins secreted by Salmonella 
Pathogenicity Island 2-encoded type three secretion system (TTSS-2). Although immuni-
zation with a live attenuated vaccine resulted in a moderate reduction of the IL-10−/− mice 
susceptibility to develop intestinal inflammation due to previous S. Typhimurium infection, 
it did not prevent bacterial persistence. Our results suggest that persistent S. Typhimurium 
infection may increase the susceptibility of mice to develop inflammation in the intestine, 
which could be associated with virulence proteins secreted by TTSS-2.
Keywords: Salmonella enterica serovar Typhimurium, inflammatory bowel disease, colitis, interleukin-10, 
persistence, dextran sulfate sodium
inTrODUcTiOn
Inflammatory bowel diseases (IBDs) are chronic intestinal immune disorders that include Crohn’s 
disease (CD) and ulcerative colitis (UC) (1). Both have increased their incidence worldwide in 
the last decades and are becoming an important social and economic burden (2, 3). Although the 
etiology of IBD remains unknown, the development of the disease requires a genetic component 
Abbreviations: S. Typhimurium, Salmonella enterica serovar Typhimurium; SPI, Salmonella pathogenicity island; IBD, inflam-
matory bowel disease; DSS, dextran sulfate sodium; IL-10, interleukin-10; TTSS, type three secretion system; WT, wild type; 
p.i., post-infection.
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and an environmental trigger. There are multiple genetic factors 
associated with both diseases (110 and 163 genes are associated 
with UC and CD, respectively) (4). However, genetic components 
contribute only in a minor proportion to the development of IBD 
(5). On the other hand, the development of the disease requires 
one or more environmental factors that trigger the onset of 
disease, such as certain types of foods—such as standard western 
diet—(6), estrogens (7, 8), cigarette smoke (9), age (10), dysbiosis 
(10–12), and gastrointestinal infection by enteric bacterial patho-
gens (13–15). Considering a major role of the environmental fac-
tors, pathogenic bacteria infection not only may be an important 
factor that increase the intestinal inflammation but it could be 
also related to an early onset of the disease (16).
Salmonella is a genus of Gram negative, facultative intracel-
lular and pathogenic bacteria able to infect mammals and 
other hosts (17). Salmonella enterica serovar Typhimurium 
(S. Typhimurium) is a common gastrointestinal pathogen and a 
public health problem worldwide, being the main cause of gastro-
enteritis and an important cause of zoonotic infection (18). This 
pathogen can survive and persist inside phagocytic cells, such as 
macrophages and dendritic cells, resulting in an asymptomatic 
but infectious carrier state that could be triggered by some anti-
biotic treatments (19, 20). S. Typhimurium has several virulence 
factors that prevent activation of the host immune response, 
favoring dissemination of the bacteria to other tissues (21, 22). 
Genes found in large chromosomal regions, known as Salmonella 
Pathogenicity Island 1 (SPI-1) and Salmonella Pathogenicity 
Island 2 (SPI-2), encode the most relevant virulence factors 
contributing to S. Typhimurium infection. Both pathogenicity 
islands encode type three secretion systems (TTSSs) (22, 23). 
The TTSS coded by genes in SPI-1 (TTSS-1) allows the bacte-
rial entry into non-phagocytic cells, such as intestinal epithelial 
cells (24, 25) and promote inflammation in the gastrointestinal 
tract to alter the intestinal microbiota (21). The function of the 
TTSS coded by genes in the SPI-2 (TTSS-2) is important for 
intracellular infection of phagocytic cells, prevention of antigen 
presentation by dendritic cells and inhibition of T cell activation, 
to favor infection of deep organs such as the spleen and liver 
(21, 26–28). Moreover, strains lacking TTSS-2 are less virulent 
and are not able to cause systemic infection due to an impairment 
of intracellular survival and Peyer’s patches colonization (21, 23).
Several changes take place in the epithelial barrier after an 
infection with S. Typhimurium (29, 30), which probably also 
promote a permanent alteration of the gut immune response (28). 
For this reason, S. Typhimurium has been proposed as a potential 
environmental risk factor able to trigger intestinal inflammation 
in susceptible host. To address this hypothesis, we tested whether 
S. Typhimurium infection enhance intestinal inflammation in 
two murine models for IBD: mice treated with dextran sulfate 
sodium (DSS) and interleukin (IL)-10−/− mice. In both models, 
we observed that mice previously infected with S. Typhimurium 
showed higher inflammation of the intestine, as compared 
to uninfected mice. Importantly, mice infected with virulent 
S. Typhimurium and treated with enrofloxacin still showed 
persistent bacteria in feces, spleen, and liver after 4 weeks of infec-
tion. Further, inflammation was associated to TTSS-2 expression, 
since infection with a strain lacking a functional TTSS-2 was 
unable to cause permanent inflammatory damage of the intestine. 
In summary, our results suggest that infection with S. Typhimurium 
increases the susceptibility of intestinal chronic inflammation in 
two mouse models that resemble IBD susceptible patients, due to 
the ability of the bacteria to cause persistent infection.
MaTerials anD MeThODs
Mice
Six to eight-weeks-old female C57BL/6 wild-type (WT) mice 
and interleukin-10 knockout mice (IL-10−/−) were obtained from 
Jackson Laboratory (Bar Harbor, ME, USA) and maintained in the 
specific pathogen-free animal facility at the Facultad de Ciencias 
Biológicas, Pontificia Universidad Católica de Chile. This study 
was approved by the Scientific Ethical Committee for Animal 
and Environment Care of the Pontificia Universidad Católica de 
Chile and the Scientific Ethical Committee for Research Biosafety 
(Protocol number 160715006). Experiments were conducted 
in agreement to institutional and international Guidelines for 
Animal Care.
Bacterial strains and growth conditions
Salmonella enterica serovar Typhimurium 14028 was originally 
obtained from the America Type Culture Collection and kindly 
provided by Dr. Carlos Santiviago, Universidad de Chile, 
Santiago, Chile. The WT or mutants strains were stored at −80°C 
in Luria-Bertani (LB) medium supplemented with 20% glycerol. 
To prepare infection doses, a small aliquot of the frozen bacteria 
was inoculated in LB medium and grown with agitation at 37°C, 
overnight. Then, bacteria were diluted 1/100 in LB medium and 
grown with agitation at 37°C until OD600 nm equal to 0.6 was reached. 
Mutant strains ΔTTSS-1 (invC) was generated by Eichelberg and 
colleagues by inserting a kanamycin resistance cassette by double 
homologous recombination (31). The ΔTTSS-2 and ΔSPI-2 were 
generated Tobar and colleagues (26) by replacing the spiC gene 
and the whole SPI-2 by a kanamycin cassette, respectively, using 
allelic exchange. All mutant strains were selected using LB media 
supplemented with 50 µg/ml kanamycin.
Mouse infection assays and enrofloxacin 
Treatment
Six to eight-weeks-old female C57BL/6 IL-10−/− mice were 
infected with 1 ×  106  CFU of S. Typhimurium 14028 WT or 
mutant strains ΔTTSS-1, ΔTTSS-2, and ΔSPI-2 contained in 
200 µl of sterile saline solution (PBS) by intragastric gavage (i.g.). 
At 7 days post-infection (days p.i.), mice were treated with 2 mg/
ml enrofloxacin (Centrovet Ltda, Santiago, Chile) in drinking 
water for 21  days. After enrofloxacin treatment, mice received 
regular drinking water for 14 days until the end of the experiment 
(42 days p.i.). For C57BL/6 WT mice infection, 1 × 105 CFU of S. 
Typhimurium were administered by i.g. and enrofloxacin treat-
ment was started at day 4 p.i. After 21 days p.i., mice received 
regular drinking water until the end of the experiment (39 days 
p.i.). In the acute colitis experimental model, 2% of DSS was 
added to drinking water from day 38 to day 44 p.i. Percentage of 
survival, weight variations, and clinical symptoms were evaluated 
3Schultz et al. Persist Salmonella Infection and IBD
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1166
until the end of the experiments and classified according to spe-
cific clinical scores.
induction of acute colitis
Colitis was induced in infected and uninfected mice by adminis-
tration of drinking water supplemented with 2% DSS (molecular 
weight 36–50  kDa, Biomedicals, OH, USA) for 7  days. Clinical 
symptoms were evaluated daily by scoring the body weight loss, 
changes in stool consistency, and presence of blood in feces. The coli-
tis score was determined as explained in Table S1 in Supplementary 
Material, according to a protocol modified from Chassaing et al. 
(32). At 7 days post DSS-colitis induction, mice were euthanized, 
and ileum and colon segments were stored for histological analyses.
hematoxylin–eosin staining  
and histopathology analyses
Different portions of the intestine (ileum, ascending colon, trans-
verse colon, descending colon, and cecum) were recovered to 
assess histopathological damage. Tissue portions were fixed in 4% 
paraformaldehyde, included in paraffin, cut into micro-sections 
(3–4 µm thickness), mounted on glass slides, and finally stained 
with hematoxylin (Harris hematoxylin, Thermo) and eosin Y 
solution (0.5% aqueous, Merk). Histopathological analyses were 
performed by a blinded observer, considering different param-
eters of inflammation, as explained in Table S2 in Supplementary 
Material. Images were obtained in a Zeiss microscope at the 
Advance Microscopy Unit of the School of Biological Sciences, 
Pontificia Universidad Católica de Chile.
Bacterial load Quantification
To evaluate bacterial loads in the spleen, liver, and mesenteric 
lymph nodes (mLNs), samples of the different organs were 
homogenized, serially diluted in sterile PBS, and seeded onto 
LB, MacConkey, or Salmonella-Shigella agar. Plates were supple-
mented with kanamycin (50 μg/ml) when mutant strains TTSS-1 
or TTSS-2 were tested.
enrichment Protocol
Salmonella enterica serovar Typhimurium isolation from feces was 
perform using ISO 6579:2002(E) adapted protocol. Briefly, feces 
were homogenized, inoculated on 5 ml of APT broth (Difco BD) 
supplemented with 20  µg/ml of novobiocin (Sigma) and incu-
bated for 24 ± 2 h 37°C. Then, positive samples were cultured on 
modified semi-solid Rappaport Vassiliadis Agar (MSRV, Oxoid) 
supplemented with novobiocine (33) and incubated at 41.5 ± 1°C 
between 24 and 48 h. Samples with white diffuse growing were cul-
ture on Xylose Lysine Deoxycholate Agar (XLD, Medium, Difco, 
BD) 37 ± 1°C for 24 ± 3 h. To confirm that the colonies obtained 
were Salmonella, a PCR to detect the invA gene was performed.
immunization assays
To prepare vaccine doses, ΔSPI-2 mutant strain was grown in 
liquid LB medium with agitation at 37°C until OD600 equal to 0.6 
was reached. For immunization, IL-10−/− mice received 1 × 106 
CFUs of ΔSPI-2 strains, contained in 200  µl of sterile PBS, by 
intragastric administration. At day 14 post-immunization, mice 
received a boost under the same conditions described before. 
At day 21 post-immunization, mice were challenged intragastri-
cally with 1 × 106 CFU of S. Typhimurium WT. At 7-days p.i., 
mice were treated with enrofloxacin (2 mg/ml) in drinking water 
for 21  days. Percentage of survival, weight loss, and bacterial 
loads were evaluated until day 42 p.i.
anti-S. Typhimurium antibodies Detection 
in serum
The detection of anti-S. Typhimurium antibodies in serum was 
determined by enzyme-linked immunosorbent assay (ELISA). 
Each wells of the ELISA plate coated with 50 µl of a solution of 
heat killed S. Typhimurium grown at OD600 0.5–0.6 and incubated 
overnight at 4°C. Then, wells were blocked with bovine serum 
albumin 10% and incubated overnight at 4°C. After three washes, 
serum of immunized/infected and unimmunized/infected animals 
obtained at 63 days post-immunization was added to each well in 
different dilution (1/8; 1/16; 1/32; 1/64; 1/128) and incubated over-
night at 4°C. The Donkey anti-mouse IgG HRP (1:1,000) or Goat 
anti-mouse IgA secondary antibody were added after washing and 
incubated at room temperature for 2 h. 50 µl of TMB was added 
and incubated for 5 min in darkness. The reaction was stopped 
by adding 50 µl of 2N H2SO4. The absorbance of the plates was 
measured at 450 nm using an ELISA plate reader. As a positive 
control, 50 µl of the commercial antibody anti-S. Typhimurium 
(clone 1E6, ab8274, abcam) 1:100 was included in the assay.
statistical analysis
Statistical analyses were performed using Prism v7 (GraphPad 
Software, San Diego, CA, USA). Multiple comparisons two 
one-way ANOVA with Bonferroni post-test were used to assess 
whether the means of more than two groups change significantly 
with respect a second variable. Body weight changes were ana-
lyzed using two-way ANOVA with Dunnetts post-test. Unpaired 
Mann–Whitney test were used to assess whether the means of 
two groups differed significantly. Two-way ANOVA analysis was 
used in some experiment with Kruskal–Wallis post-test.
resUlTs
infection increases S. Typhimurium the 
susceptibility of Mice to Develop intestinal 
inflammation due to acute chemical 
Damage
To evaluate whether a previous infection with S. Typhimurium 
could promote an increase in intestinal inflammation produced 
by the administration of DSS 2%, we performed an intragastric 
infection of C57BL/6 mice with 1  ×  105  CFU of virulent S. 
Typhimurium. After 4 days post-infection (days p.i.), mice were 
treated with enrofloxacin for 21 days to clear bacterial infection 
(Figure 1A). Then, after 39 days p.i., DSS 2% was administered 
to mice in drinking water for 7 days. As shown in the Figure 1B, 
mice infected with S. Typhimurium showed a slightly increase 
in weight loss in the last three days of the treatment with DSS, 
as compared to control mice. In addition, a colitis score that 
consider the presence of occult blood and stool aspect (Table 
S1 in Supplementary Material) was evaluated during the DSS 
FigUre 1 | Intestinal inflammation due to colitis induction by dextran sulfate sodium (DSS) 2% is increased by previous Salmonella enterica serovar Typhimurium  
(S. Typhimurium) infection. (a) C57BL/6 mice were orally infected with 1 × 105 CFU of S. Typhimurium wild type (WT). Four days post-infection (days p.i.) mice were  
orally treated with enrofloxacin (2 mg/ml) for 3 weeks, left untreated for 12 days, and treated orally with DSS 2% for 7 days. (B) Body weight of uninfected and 
previously infected C57BL/6 mice were recorded on a daily basis for 44 days. (c) Clinical colitis score recorded during the period of colitis induction by DSS 2%, 
between 37 and 44 days p.i. (D) Average histopathology score of descending colon, performed for three mice per group. (e) Representative images of descending 
colon at day 44 p.i. between uninfected-DSS and infected-DSS treated mice (4 μm descending colon section stained with H&E and observed in optical microscope 
at 10× magnification). Data shown are mean ± SEM of one experiment with six mice per group. Body weight changes were analyzed using two-way ANOVA with 
Bonferroni post-test. P < 0.07 between uninfected-DSS 2% and infected-DSS 2% treated mice at 44 days p.i. Histopathology score was analyzed by Mann–
Whitney U-test. Data shown are mean ± SEM *P < 0.05.
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treatment, but it did not show differences between the two groups 
(Figure 1C). However, at the end of experiment (44 days p.i.), we 
observed that mice infected with S. Typhimurium and treated with 
DSS 2% showed significantly increased inflammation in descend-
ing colon, as compared to uninfected mice that were equally 
treated with DSS 2% (Figures 1D,E). No pathological features of 
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disease were observed in any other intestinal portions evaluated 
(Figure S1 in Supplementary Material). These results suggest that 
WT S. Typhimurium leads to an increased intestinal inflamma-
tion only in the descending colon, which could be associated to 
the pathology generated by the administration of DSS.
S. Typhimurium infection increases the 
susceptibility of il-10−/− Mice to Develop 
spontaneous intestinal inflammation  
in an sPi-2-Dependent Manner
To evaluate colitis induction in another IBD model, IL-10−/− mice 
were intragastrically infected with 1 × 106 CFUs of S. Typhimurium. 
After 7 days of infection, mice were treated with enrofloxacin and 
monitored up to day 42 days p.i. (Figure 2A). For IL-10−/− mice, 
we used a dose and an infection time that was higher than the 
dose and time chosen for WT mice, because the former mice are 
more resistant to S. Typhimurium infection (34). As shown in 
Figure 2B, infected IL-10−/− mice experienced significant weight 
loss from 1 to 10 days p.i. (showing approximately a 10% weight 
reduction) and started to recover their weight until the end of the 
experiment, which correlated with enrofloxacin treatment. At the 
end of the experiment (42 days p.i.), the intestine was evaluated 
for spontaneous inflammation and, as observed in Figure  2C, 
IL-10−/− mice previously infected with virulent S. Typhimurium 
showed an increased inflammation in the ileum and ascending 
colon, as compared to control uninfected mice.
Next, we evaluated whether the inflammation of a specific 
intestinal portion observed in IL-10−/− mice infected with virulent 
S. Typhimurium depended of specific virulence genes of the bacte-
rium. To address this aim, mice were infected with S. Typhimurium 
strains lacking functional TTSS-1 or TTSS-2 and an experiment 
similar to the one described before was performed (Figure 2A). 
As shown in Figure 2B, mice infected with the ΔTTSS-1 strain 
also showed a significant weight loss as compared to uninfected 
mice, while mice infected with the ΔTTSS-2 strain showed no sig-
nificant weight loss. Furthermore, a similar pattern of inflamma-
tion in ileum and ascendant colon was observed in mice infected 
with the ΔTTSS-1 strain, while none of the mice infected with 
the ΔTTSS-2 strain showed significant intestinal inflammation 
(Figures  2C,D). Intriguingly, mice infected with the ΔTTSS-1 
showed increased inflammation also in transverse (Figure  3A) 
and descending colon (Figure 3B), as compared to mice infected 
with WT S. Typhimurium or control mice (Figure  3C). These 
results suggest that permanent inflammation in IL-10−/− mice due 
to S. Typhimurium infection depends of the bacterial ability to 
invade and survive within phagocytic cells, rather than its capacity 
to invade intestinal epithelium and cause acute infection.
The increased susceptibility of Mice  
to Develop intestinal inflammation due  
to Previous S. Typhimurium infection  
is associated to Persistent Bacteria  
in Tissues
To determine whether the increased intestinal inflammation 
in both WT and IL-10−/− mice was associated to a persistent 
S. Typhimurium infection, bacterial loads were evaluated at 39 
and 42 days p.i., respectively, in liver, spleen, and mLNs. In both 
mice strains infected with S. Typhimurium WT, the bacteria were 
detected in the spleen and liver in 20–50% of the infected mice, 
even after a treatment with enrofloxacin that lasted for 3 weeks 
(Table 1). As shown in Table 1, there was no difference in the 
histopathology score in mice that had persistent bacteria in 
internal organs as compared to those with no persistent bacteria. 
However, we observed that at 39 days p.i., eight out of nine infected 
WT mice had significant amounts of S. Typhimurium in the feces 
(Figure  4), although persistent bacteria were not detected in 
Peyer’s Patches or cecum content (data not shown). Furthermore, 
we evaluated the effectiveness of the enrofloxacin treatment by 
enrichment protocol, which confirmed the depletion of the intes-
tinal microbiota during the enrofloxacin treatment, as well as its 
recovery at the end of the treatment (not shown). These results 
suggest that most of the mice infected and treated with antibiotics 
showed a relapsing infection after antibiotic withdrawn, although 
we were not able to detect the persistent bacteria in deep tissues 
in all of the mice included in the study. In IL-10−/− mice infected 
with the ΔTTSS-1 strain, we found that only one of the mice 
included in all the experiments showed detectable bacterial loads 
in spleen, liver, and mLNs, while none of the mice infected with 
the ΔTTSS-2 strain showed bacteria in internal organs (Table 1). 
These results suggest that the intestinal inflammation induced by 
S. Typhimurium in IL-10−/− mice could depend on the capacity of 
the bacterium to cause a persistent infection in the host.
Oral immunization With an attenuated 
live Vaccine reduces intestinal 
inflammation, but it Did not Prevent 
Persistent infection in S. Typhimurium-
infected il-10−/− Mice
The results obtained in the previous experiments led us to 
hypothesize that immunization of IL-10−/− mice with a live 
attenuated strain of S. Typhimurium could be beneficial to 
prevent bacterial persistence and intestinal inflammation. To 
approach this hypothesis, IL-10−/− mice were intragastrically 
immunized with 1 × 106 CFUs of the ΔSPI-2 strain. At day 14, 
a second oral dose of the same strain was administered to these 
mice. Mice were then challenged at day 21 post-immunization 
with virulent S. Typhimurium, as described above, to evaluate 
whether immunization reduced their susceptibility to develop 
spontaneous intestinal inflammation, as well as bacterial persis-
tence (Figure  5A). To corroborate whether the immunization 
strategy induced an immune response against Salmonella, we 
examined the anti-Salmonella antibodies at 63 days post-immu-
nization in the immunized mice and detected elevated IgG and 
IgA levels (Figure S2 in Supplementary Material).
In agreement with our previous results, unimmunized and 
infected IL-10−/− mice showed a significantly higher level of 
spontaneous inflammation in ileum, ascending colon, and 
transverse colon, as compared to unimmunized and uninfected 
IL-10−/− mice (Figure 5B). Importantly, we observed that IL-10−/− 
mice that were immunized with the ΔSPI-2 strain previous to 
S. Typhimurium infection showed a mild reduction in the 
FigUre 2 | Previous Salmonella enterica serovar Typhimurium (S. Typhimurium) infection increase the susceptibility of spontaneous intestinal inflammation of 
interleukin (IL)-10−/− mice. (a) IL-10−/− mice were orally infected with 1 × 106 CFU of S. Typhimurium (STM) wild type (WT), ΔTTSS-1, or ΔTTSS-2. Seven days 
post-infection (days p.i.) mice were orally treated with enrofloxacin (2 mg/ml) for 3 weeks, left untreated for 14 days and euthanized to evaluate spontaneous 
intestinal inflammation. (B) Body weight were recorded on a daily basis for 42 days after infection. (c) Average histopathology score for ileum and ascending colon 
of 6–10 IL-10−/− mice included in each group. (D) Representative images of on the intestines of IL-10−/− mice infected with S. Typhimurium WT, ΔTTSS-1, or 
ΔTTSS-2 (4 µm ileum and ascending colon section stained with H&E and observed in optical microscope at 10× magnification). Body weight changes were 
analyzed using two-way ANOVA with Dunnetts post-test. Mice infected with WT (a, α) and TTSS-1 (b, β) were compared with mice uninfected and treated with 
antibiotics (UI/ATB). Data shown are mean ± SEM of three independent experiment with 8 mice uninfected; 10 mice infected with WT strain; 10 mice infected with 
ΔTTSS-1 strain; and 9 mice infected with ΔTTSS-2 strain. Statistical significance was indicated by letters: a, b: *P < 0.05; α, β: **P < 0.01. Histopathology score 
was analyzed by one-way ANOVA with Kruskal–Wallis post-test. Data shown are mean ± SEM *P < 0.05; compared with uninfected mice. Tissue damage and 
inflammatory infiltration are indicated (arrow).
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FigUre 3 | Previous Salmonella enterica serovar Typhimurium (S. Typhimurium) infection increases the susceptibility of spontaneous inflammation of colon of 
interleukin (IL)-10−/− mice in a 2-encoded type three secretion system (TTSS-2)-dependent fashion. Average histopathology score for (a) transverse colon and  
(B) descending colon of 6–10 IL-10−/− mice included in each group. (c) Representative images of the intestines of IL-10−/− mice infected with S. Typhimurium wild 
type (WT), ΔTTSS-1, or ΔTTSS-2 (4 µm transverse and descending colon sections stained with H&E and observed in optical microscope at 10× magnification). 
Data shown are mean ± SEM of three independent experiment with 8 mice uninfected; 10 mice infected with WT strain; 10 mice infected with ΔTTSS-1 strain; and 
9 mice infected with ΔTTSS-2 strain. Histopathology score was analyzed by one-way ANOVA with Kruskal–Wallis post-test. Data shown are mean ± SEM 
*P < 0.05; compared with uninfected mice. Tissue damage and inflammatory infiltration are indicated (arrow).
TaBle 1 | Relationship between presence of persistent S. Typhimurium isolated from internal organs vs colonic histological score of mice intragastrically infected and 
treated for 3 weeks with enrofloxacin.
experimental group Days post-infection Total mice % of persistent mice colon score
Persistent bacteria
colon score
no persistent bacteria
C57BL/6 + STM WT 39 6 50 2.3 1.9
IL-10−/− + STM WT 42 9 33.3 1.9 1.5
IL-10−/− + STM ΔTTSS-1 42 10 10 1.33 2.3
IL-10−/− + STM ΔTTSS-2 42 9 0 0 1.7
IL-10−/− unimmunized 63 7 57.1 1.9 1
IL-10−/− immunized 63 8 50 0.4 0.5
WT or IL-10−/− mice were intragastrically infected with 1 × 105 or 1 × 106 CFU of S. Typhimurium, respectively and bacterial loads were quantified at the end of the experiments 
(39, 42, or 63 days post-infection, respectively) in spleen, liver, and mLNs. The homogenized tissues were cultured into MacConkey agar, as described in Section “Materials and 
Methods.” The histopathological score of colon (ascending, transverse, and descending colon) did not show differences with respect to non-persistent mice.
S. Typhimurium, Salmonella enterica serovar Typhimurium; WT, wild type; TTSS, type three secretion system; mLNs, mesenteric lymph nodes; IL, interleukin.
7
Schultz et al. Persist Salmonella Infection and IBD
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1166
susceptibility to develop spontaneous intestinal inflammation in 
ileum, ascending, and transverse colon (Figure 5B). Despite the 
histopathological score obtained for immunized and infected mice 
were not significantly different to the scores obtained for unin-
fected mice, differences were not found either between the scores 
obtained for immunized and infected mice and unimmunized 
and infected mice (Figures  5B,C; Figure S3 in Supplementary 
Material). These results suggest that immunization could reduce 
but not prevent the inflammation. Furthermore, bacterial loads 
in spleens and livers were equivalent in immunized and unim-
munized infected mice (Table 1). Importantly, the bacteria found 
in the internal tissues of immunized mice were the virulent WT 
FigUre 4 | Salmonella enterica serovar Typhimurium (S. Typhimurium) is 
excreted in feces after 39 days of infection in wild type (WT) mice, despite 
enrofloxacin treatment. C57BL/6 WT mice were infected with 1 × 105 CFU of 
S. Typhimurium WT. Four days post-infection (days p.i.) mice were orally 
treated with enrofloxacin (2 mg/ml) for 3 weeks, and then left untreated for 
14 days. Bacterial loads were quantified at 39 days post-infection by seeding 
feces into Salmonella-Shigella agar, as described in Section “Materials and 
Methods.” Data shown include two separated experiment, nine mice in total.
8
Schultz et al. Persist Salmonella Infection and IBD
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1166
S. Typhimurium strain used for the challenge, not the vaccine 
strain, because immunized mice did not show bacterial loads 
in any tissue previous S. Typhimurium WT challenge (data not 
shown). These results suggest that the vaccine and immunization 
scheme used here promoted a reduction in the susceptibility of 
IL-10−/− mice to develop spontaneous inflammation, but it did 
not prevent S. Typhimurium persistence.
DiscUssiOn
Inflammatory bowel diseases are caused by an abnormal immune 
response in genetic susceptible host, which results in inflamma-
tion and intestinal tissue damage. Although the etiology of this 
disease is poorly understood, it is widely accepted that an inap-
propriate immune response toward commensal bacteria is a cru-
cial part of the pathogenesis (35). Interestingly, enteric infections 
caused by pathogens, such as Salmonella and Campylobacter, 
have been associated with the onset and development of IBD in 
humans (13, 23, 36). However, experimental assays to determine 
whether previous S. Typhimurium infection plays a role in the 
development of IBD in susceptible hosts has not been done 
yet. Here, we demonstrate that mice previously infected by S. 
Typhimurium generate higher intestinal inflammation in two 
different mouse models that resemble IBD features.
Although no differences in weight loss or clinical scores 
were observed between uninfected and previously infected 
mice during the colitis induction in DSS administration model, 
mice that were previously infected by S. Typhimurium showed 
an increased inflammation of descending colon after DSS 
treatment. It is important to note that ascending and transverse 
colon are the most exposed sites to Salmonella infection, as they 
are closer to the terminal ileum where such infections mainly 
occur. Importantly, previous S. Typhimurium infection also 
resulted in a significantly enhanced spontaneous inflammation 
of IL-10−/− mice, which showed higher histopathological score 
in ileum and ascending colon, as compared to mice that were 
not previously infected by the bacterium. The exacerbation of the 
inflammation in these two mouse model of IBD might be due to 
the permanent consequences of the S. Typhimurium infection in 
the intestine. For instance, previous reports show that recurrent 
S. Typhimurium infection induce the expression of NEU3 and, 
in consequence, decrease the levels of intestinal alkaline phos-
phatase in this tissue. The reduction of the alkaline phosphatase 
affects the levels of intestinal LPS and induces an inflammatory 
response in mice (37).
Importantly, we observed persistent S. Typhimurium 
infection, mainly in liver and spleen of IL-10−/− and WT mice 
treated with enrofloxacin after infection. This observation is in 
agreement with the mouse typhoid model, where it has been 
described that Salmonella persists in biofilms on gallstones (38, 
39), as well as in liver, spleen, and mLNs, where the bacteria 
persist within macrophages (40, 41). Our data are also in agree-
ment with several recent reports showing that antibiotic treat-
ment promotes the selection of “persisters,” which are clones of 
Salmonella that undergo metabolic and genetic modifications 
during infection of mice treated with antibiotics. These persist-
ers become insensitive to the action of antibiotics and are not 
able to replicate and reside intracellularly (41–44). Supporting 
this idea, a recent report has shown that an acetyltransferase 
toxin denominated TacT, which blocks protein synthesis by 
affecting the function of tRNA molecules, is required by S. 
Typhimurium to become antibiotic insensitive and persist 
in the infected tissues of mice (45). Importantly, it has been 
demonstrated that in the absence of antibiotics, persisters 
can resume active growth from infected tissues and account 
for relapsing infections (43, 45). These studies suggest that 
the reservoir cell for these non-replicating bacteria are able to 
protect them from the action of the antibiotics, resulting in cell 
permanently infected.
In the experimental settings of our study, although we 
detected persistent S. Typhimurium in deep organs in around 
50% of both C57BL/6 WT and IL-10−/−, we did observe a high 
percentage of mice that shed bacteria in feces at the end of the 
experiment, when antibiotic treatment was withdrawn. This 
observation suggests that the method used to detect persistent 
S. Typhimurium infection is not sensitive enough, which might 
produce false negatives for tissues where the bacterial load is very 
low. This imply the necessity of more sensitive techniques for the 
evaluation of persistent S. Typhimurium in deeper organs, such 
as qRT-PCR. These results suggest that the higher susceptibility 
to develop intestinal inflammation in mice might be related 
relapsing episodes of S. Typhimurium infection, which could be 
enhancing a pro-inflammatory environment in intestinal tissue. 
In support of this hypothesis are the results of the immunization 
assay performed here. Although immunization with ΔSPI-2 
strain was unable to prevent persistence of S. Typhimurium in 
spleen and liver of infected mice, it did induce an IgG and IgA 
humoral immune response against the WT strain. As a matter 
of fact, immunized and infected mice showed less inflammation 
that unimmunized and infected mice, despite the presence of 
persistent bacteria in deep tissues in both groups. It is possible 
FigUre 5 | Immunization reduces the increased susceptibility of interleukin (IL)-10−/− for intestinal inflammation due to previous Salmonella enterica serovar 
Typhimurium (S. Typhimurium) infection. (a) IL-10−/− mice were immunized with 1 × 106 CFU of attenuated S. Typhimurium strain ΔSPI-2 at day 0 and received a 
boost at day 14. Subsequently, mice were challenged with virulent S. Typhimurium on day 21. Seven days post-challenge, mice were orally treated with enrofloxacin 
(2 mg/ml) for 3 weeks, left untreated for 14 days and euthanized at 63 days post-immunization to evaluate spontaneous intestinal inflammation. (B) Average 
histopathology score for ileum, ascending, and transverse colon of seven IL-10−/− mice included in each group. (c) Representative images of the intestines of 
IL-10−/− mice, unimmunized-uninfected mice, unimmunized-infected and immunized-infected mice (4 µm ileum and ascending colon section stained with H&E and 
observed in optical microscope at 10× magnification). Arrows indicate inflammatory cellular infiltration and erosion. Histological score analyzed by one-way ANOVA 
with Kruskal–Wallis post-test. Data shown are mean ± SEM of two independent experiments with three to four mice per group. *P < 0.05, compared uninfected 
with immunized-infected or unimmunized-infected mice.
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that specific anti-Salmonella immunoglobulin levels in serum 
and mucosa of immunized mice were efficient in the clearance 
of relapsing bacteria (46, 47), or might potentially generate a 
different immune response against these re-emerging bacteria, 
preventing in turn inflammation of the intestinal tissue.
In the streptomycin mouse model, which is efficiently colo-
nized by S. Typhimurium, TTSS-2 mutants invade epithelial cells 
through TTSS-1 and elicit early inflammatory responses in the 
intestine, but are incapable of spreading systemically (48). This 
is in agreement with our results, showing that translocation of 
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FigUre s1 | C57BL/6 wild-type (WT) mice previously infected with Salmonella 
typhimurium have similar intestinal tissue damage in ileum, ascending, and 
transverse colon as uninfected mice. WT mice were orally infected with 105 CFU 
of S. typhimurium WT. (a) Histopathology score was analyzed by one-way 
ANOVA with Kruskal–Wallis post-test. (B) At day 44 p.i. the intestines were 
removed and embedded in paraffin. 4 μm section of ileum, ascending, and 
transverse colon section were stained with H&E and observed in optical 
microscope at 10× magnification. Data show mean ± SEM ns, non-significant; 
compared with uninfected-treated with 2% DSS.
FigUre s2 | Immunization of IL-10−/− mice did not prevent increase 
susceptibility to develop inflammation in descending colon due to previous 
S. typhimurium infection. (a) At day 63 post immunization, the intestines were 
removed and embedded in paraffin. 4 μm sections of descending colon section 
were stained with H&E and observed in optical microscope at 10× magnification. 
(B) Histological score was analyzed by one-way ANOVA with Kruskal–Wallis 
post-test. Data show mean ± SEM ns, non-significant; compared uninfected 
mice with immunized-infected mice or unimmunized-infected mice. Differences 
between groups immunized-infected and unimmunized-infected were found 
using ANOVA and Tukey as post-test, *P < 0.05. Infiltrated and erosion are 
indicated respectively (arrow).
FigUre s3 | Immunization of IL-10−/− mice increase antibody immune response 
against S. typhimurium WT. (a,B) The measurement of IgA against 
S. typhimurium WT was made in ileum and colon content of IL-10−/− mice 
immunized with ΔSPI-2 and challenged with S. typhimurium WT at day 63 post 
immunization as described in material and methods. (c) The measure of IgG 
against S. typhimurium WT was made in serum of IL-10−/− mice immunized with 
ΔSPI-2 and challenged with S. typhimurium WT at day 63 post immunization as 
described in material and methods. Data show mean ± SEM compared 
immunized-infected mice or unimmunized-infected mice. Differences between 
groups immunized-infected and unimmunized-infected were found using ordinary 
one-way ANOVA, **P < 0.05.
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